Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy.
Anti-Obesity Agents
/ administration & dosage
Bupropion
/ administration & dosage
Epidemics
/ prevention & control
Global Health
Humans
Liraglutide
/ administration & dosage
Naltrexone
/ administration & dosage
Obesity
/ drug therapy
Orlistat
/ administration & dosage
Precision Medicine
/ methods
Weight Loss
/ drug effects
Obesity
lorcaserin
naltrexone-bupropion
orlistat
pharmacotherapy
phentermine-topiramate and liraglutide
Journal
Endocrine, metabolic & immune disorders drug targets
ISSN: 2212-3873
Titre abrégé: Endocr Metab Immune Disord Drug Targets
Pays: United Arab Emirates
ID NLM: 101269157
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
10
2019
revised:
30
03
2020
accepted:
01
04
2020
pubmed:
16
5
2020
medline:
5
8
2021
entrez:
16
5
2020
Statut:
ppublish
Résumé
The increase in global obesity rates over the past three decades has been remarkable, a true epidemic, both in developed and in developing countries. The projections, based on current trends, suggest an increase in the prevalence of obesity at 60% in adult men, 40% in adult women and 25% in children in 2050. Given the limitations of lifestyle and surgery interventions bariatric, drug therapy approaches for the treatment of obesity, therefore become important options. The purpose of this review is a review of the literature, based on research on MEDLINE until 2019, on the possible pharmacological options in the treatment of obesity. Currently, the FDA has approved several molecules for the treatment of obesity, both in monotherapy and in combination. Pharmacological monotherapies focus mainly on a single protein target and include orlistat, lorcaserin and liraglutide while the combination molecules propose a multitarget approach and include phentermine/topiramate and naltrexone/bupropion. All the approved drugs showed, in the different studies, a weight reduction of at least 5%, compared to placebo, in 52 weeks of observation. Phentermine-topiramate and liraglutide have been associated with the highest probability of at least 5% weight loss. Liraglutide and naltrexone-bupropion had the lowest rates of therapy discontinuation due to adverse events. The drugs, associated with the standard diet and/or exercise protocols, represent a good therapeutic opportunity to allow not only weight loss but also to reduce the risk of developing diseases caused by obesity, particularly cardiovascular diseases, and to maintain the set objectives over time. However, future research on the pharmacological treatment of obesity should encourage greater personalization of therapy, given the differences in safety, efficacy and response to therapy, in the different subpopulations of patients with obesity.
Sections du résumé
BACKGROUND
BACKGROUND
The increase in global obesity rates over the past three decades has been remarkable, a true epidemic, both in developed and in developing countries. The projections, based on current trends, suggest an increase in the prevalence of obesity at 60% in adult men, 40% in adult women and 25% in children in 2050. Given the limitations of lifestyle and surgery interventions bariatric, drug therapy approaches for the treatment of obesity, therefore become important options.
AIM
OBJECTIVE
The purpose of this review is a review of the literature, based on research on MEDLINE until 2019, on the possible pharmacological options in the treatment of obesity.
RESULTS
RESULTS
Currently, the FDA has approved several molecules for the treatment of obesity, both in monotherapy and in combination. Pharmacological monotherapies focus mainly on a single protein target and include orlistat, lorcaserin and liraglutide while the combination molecules propose a multitarget approach and include phentermine/topiramate and naltrexone/bupropion. All the approved drugs showed, in the different studies, a weight reduction of at least 5%, compared to placebo, in 52 weeks of observation. Phentermine-topiramate and liraglutide have been associated with the highest probability of at least 5% weight loss. Liraglutide and naltrexone-bupropion had the lowest rates of therapy discontinuation due to adverse events.
CONCLUSION
CONCLUSIONS
The drugs, associated with the standard diet and/or exercise protocols, represent a good therapeutic opportunity to allow not only weight loss but also to reduce the risk of developing diseases caused by obesity, particularly cardiovascular diseases, and to maintain the set objectives over time. However, future research on the pharmacological treatment of obesity should encourage greater personalization of therapy, given the differences in safety, efficacy and response to therapy, in the different subpopulations of patients with obesity.
Identifiants
pubmed: 32410565
pii: EMIDDT-EPUB-106651
doi: 10.2174/1871530320666200515112853
doi:
Substances chimiques
Anti-Obesity Agents
0
Bupropion
01ZG3TPX31
Naltrexone
5S6W795CQM
Liraglutide
839I73S42A
Orlistat
95M8R751W8
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1232-1243Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.